Cagrilintide Dosage: How Much to Take, When & How

Cagrilintide Dosage: How Much to Take, When & How

Overview

Cagrilintide is a long-acting amylin receptor agonist administered via once-weekly subcutaneous injection. It is designed to reduce appetite, slow gastric emptying, and promote weight loss by mimicking the endogenous pancreatic hormone amylin. The standard dosing protocol escalates from 0.16 mg to a maximum of 2.4 mg weekly over several weeks.

Important Note: Cagrilintide remains an investigational compound not yet approved by the FDA or EMA. This guide is educational and should not replace consultation with a healthcare provider. Access to cagrilintide outside clinical trials is limited and carries significant regulatory and quality-assurance risks.

Standard Dosing Protocol

Cagrilintide follows a dose-escalation schedule to improve tolerability and minimize gastrointestinal side effects during the initiation phase.

Weekly Dose Escalation Schedule

The standard dosing progression is:

• Week 1–4: 0.16 mg once weekly
• Week 5–8: 0.32 mg once weekly
• Week 9–12: 0.48 mg once weekly
• Week 13–16: 0.64 mg once weekly
• Week 17–20: 0.8 mg once weekly
• Week 21+: 1.2 mg to 2.4 mg once weekly (maintenance)

Most clinical trial participants reached a maintenance dose of 2.4 mg weekly by week 20–24 of treatment.

Dosing Frequency

• Administration: Once per week (every 7 days)
• Route: Subcutaneous injection
• Timing: Consistent day and time each week (e.g., every Monday morning)
• Injection site rotation: Alternate injection sites (abdomen, thigh, upper arm) to minimize local reactions

Duration of Action

Due to fatty acid acylation enabling albumin binding, cagrilintide has an approximate half-life of 7 days, making once-weekly dosing pharmacologically feasible and convenient for users.

Dosing by Goal

Weight Loss (Primary Indication)

Recommended dose range: 2.4 mg once weekly (maintenance)

Clinical evidence supports this dosing tier:

• CagriSema combination (cagrilintide 2.4 mg + semaglutide 2.4 mg): Produced 15% mean body weight reduction in adults with obesity (68-week RCT, n=2,108) vs. 4% placebo
• CagriSema in type 2 diabetes: Achieved 13.7% body weight reduction vs. 3.4% placebo (68-week RCT, n=904)
• Monotherapy (cagrilintide alone): Phase 2 data shows modest but consistent weight loss effects, though exact percentage reduction varies by individual

Timeline to results: Meaningful weight loss typically becomes apparent by week 8–12 of consistent dosing, with cumulative effects observed through 16+ weeks.

Metabolic Control & Blood Glucose

Recommended dose range: 1.2 mg to 2.4 mg once weekly

Cagrilintide's mechanism—activation of amylin receptors in the hypothalamus and brainstem—suppresses appetite, reduces glucagon secretion, and delays gastric emptying. This improves postprandial glucose control. No separate dosing protocol exists for glucose control alone; the standard escalation schedule and maintenance doses (1.2–2.4 mg) provide benefit for both weight loss and metabolic outcomes.

Blood Pressure Reduction

Recommended dose range: 2.4 mg once weekly (CagriSema combination data)

When combined with semaglutide at matching doses:

• Systolic BP reduction: 10.9 mmHg (CagriSema) vs. 2.8 mmHg placebo
• Target attainment: 63% of participants reached blood pressure targets with CagriSema vs. 32% placebo

Evidence for monotherapy blood pressure effects remains limited; most cardiovascular data comes from CagriSema combination trials.

How to Administer

Injection Technique

1. Preparation: Remove vial/pen from storage; allow to reach room temperature for 15–30 minutes if refrigerated
2. Inspection: Visually inspect the solution—should be clear and colorless. Do not use if discolored or cloudy
3. Site selection: Choose an injection site on the abdomen, thigh, or upper arm; rotate sites weekly to prevent lipohypertrophy and local irritation
4. Skin preparation: Clean injection site with an alcohol swab; allow to air dry
5. Injection: Pinch the skin, insert needle at 90 degrees, and inject slowly (over 3–5 seconds) to reduce discomfort
6. Needle removal and disposal: Withdraw needle smoothly; dispose of in a sharps container
7. Post-injection: No massage or rubbing of injection site; light pressure with clean gauze is acceptable

Storage Requirements

• Unopened vials/pens: Refrigerate at 2–8°C (36–46°F) until first use
• After first use: May be stored at room temperature or refrigerated; check product labeling for specific recommendations
• Avoid freezing: Do not freeze cagrilintide solutions
• Light protection: Store in original carton to minimize light exposure

Injection Site Rotation

Proper rotation reduces the risk of injection site reactions (redness, swelling, bruising). A typical 4-week rotation pattern:

• Week 1: Right abdomen
• Week 2: Left abdomen
• Week 3: Right thigh
• Week 4: Left thigh
• (Repeat)

Cycling & Timing

Maintenance Phase Duration

Once the maintenance dose (typically 2.4 mg weekly) is reached, cagrilintide is designed for ongoing, continuous weekly dosing. There is no evidence-based "off-cycle" period in clinical trials. Participants in phase 2 and phase 3 studies received uninterrupted weekly injections for 68+ weeks.

Consistency in Timing

Consistent weekly dosing is critical:

• Choose a specific day and time (e.g., 8 AM every Monday)
• Set reminders or use a calendar to avoid missed doses
• If a dose is missed, administer it as soon as remembered, then resume the regular schedule 7 days later

Long-Term Use

No maximum duration of cagrilintide therapy has been established in available trials. Current evidence supports use up to 68 weeks with a manageable safety profile. Long-term safety and efficacy beyond this timeframe remain under investigation.

Beginner vs. Advanced Dosing

Beginner Protocol (Initiation Phase)

Beginners should always follow the standard dose-escalation schedule:

• Start at 0.16 mg weekly
• Escalate by 0.16–0.32 mg every 4 weeks
• Progress to 2.4 mg maintenance over 20–24 weeks

Rationale: Gradual escalation minimizes nausea and vomiting, the most common side effects during initiation. Rushing escalation increases gastrointestinal intolerance.

Advanced/Experienced Dosing

Users with prior exposure to amylin agonists or GLP-1 agonists may tolerate faster escalation, but clinical trial designs did not support expedited schedules. No evidence supports skipping dose levels or escalating faster than outlined in standard protocols.

Individual Variation

Dose escalation should be adjusted based on:

• Tolerability: If GI side effects are severe, remain at current dose 1–2 additional weeks before escalating
• Response: Users experiencing excellent results at lower doses may maintain sub-maximal dosing (e.g., 1.2 mg) rather than progressing to 2.4 mg
• Comorbidities: Users with gastroparesis, severe renal impairment, or other contraindications should consult healthcare providers before use

Common Dosing Mistakes

1. Skipping the Escalation Phase

Mistake: Starting at 1.2 mg or 2.4 mg to "get results faster"
Consequence: Severe nausea and vomiting, leading to treatment discontinuation
Correct approach: Always begin at 0.16 mg and escalate gradually every 4 weeks

2. Inconsistent Injection Timing

Mistake: Injecting on different days each week (e.g., Monday one week, Wednesday the next)
Consequence: Reduced efficacy due to suboptimal amylin receptor occupancy; potential rebound appetite between doses
Correct approach: Inject on the same day and time each week

3. Missed Doses Without Adjustment

Mistake: Missing a weekly injection and resuming the following week without accounting for the missed dose
Consequence: Pharmacokinetic disruption; potential loss of appetite suppression and increased food intake
Correct approach: If a dose is missed, administer it as soon as remembered, then resume weekly dosing 7 days later

4. Rotating Injection Sites Incorrectly

Mistake: Injecting into the same location repeatedly (e.g., always the left abdomen)
Consequence: Lipohypertrophy (fat pad formation), bruising, and reduced drug absorption
Correct approach: Systematically rotate sites every 1–2 weeks among abdomen, thighs, and upper arms

5. Premature Escalation

Mistake: Advancing to the next dose before 4 weeks have elapsed to "speed up results"
Consequence: Cumulative GI side effects; poor tolerability leading to early discontinuation
Correct approach: Adhere to 4-week intervals at each dose level; only escalate if tolerated well

6. Combining with Incompatible Medications

Mistake: Adding cagrilintide without disclosing concurrent GLP-1 agonists or other appetite-suppressing agents
Consequence: Excessive nausea, vomiting, and risk of severe dehydration
Correct approach: Always disclose all medications to healthcare providers; cagrilintide is primarily investigated as a monotherapy or in combination with semaglutide (CagriSema)

Cost Considerations

Monthly cost range: $200–$600/month depending on source and geographic location

Cost-per-dose (at 2.4 mg weekly):

• Monthly (4 doses): $50–$150 per injection
• Annual cost estimate: $2,400–$7,200

Note: Cagrilintide is investigational and not covered by insurance. Pricing reflects research-grade or compounded sources, which carry regulatory and quality-assurance risks. Individuals considering cagrilintide should prioritize sourcing from established clinical trial programs or licensed pharmacies.

Summary Dosing Table

Final Disclaimer

This guide is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Cagrilintide remains an investigational compound outside clinical trial settings. Any decision to use cagrilintide should be made in consultation with a qualified healthcare provider. Access to cagrilintide outside approved clinical trials carries regulatory and quality-assurance risks. Individuals should verify the source, purity, and legality of any peptide compound before use.